Alnylam Pharmaceuticals achieved a historic milestone in the first quarter by surpassing $1 billion in quarterly product revenues for the first time, fueled by the explosive growth of its TTR franchise and the highly successful ongoing launch of AMVUTTRA.
Alnylam Pharmaceuticals (ALNY) delivered a watershed fourth-quarter earnings report, officially declaring its transition to sustainable GAAP profitability for the full year 2025. This long-awaited milestone validates the company's pioneering RNAi therapeutics platform and was propelled by the spectacular launch of Amvuttra for ATTR cardiomyopathy. Driven by the TTR franchise, Alnylam generated nearly $3 billion in combined net product revenues in 2025, an 81% surge compared to the prior year. Emboldened by its fortified financial position, management laid out an ambitious "Alnylam 2030" strategy, targeting a 25% revenue CAGR over the next five years and projecting combined net product sales to leap to between $4.9 billion and $5.3 billion in 2026.